Business
Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine®2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA – 021506 and the company will begin distribution in September 2025.
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":"MAHWAH, N.J., Aug. 19, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine®2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA – 021506 and the company will begin distribution in September 2025.","length":541,"tagName":"p"},{"type":"image","alt":"Glenmark Pharmaceuticals Ltd. Logo","displaySize":"","headline":null,"caption":"Glenmark Pharmaceuticals Ltd. Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":248,"url":"https://media.zenfs.com/en/prnewswire.com/665b8e82087cbb982ffe3ea107634a26"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QQPQSICzWHjx5eGgMRHVrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/665b8e82087cbb982ffe3ea107634a26","width":400,"height":248}}},{"type":"text","content":"According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection, 50 mg/vial and 100 mg/vial market3 achieved annual sales of approximately $60.7 million*.","length":191,"tagName":"p","attribs":{}},{"type":"text","content":" Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need."","length":411,"tagName":"p","attribs":{}},{"type":"text","content":" 1 Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication(s) listed in Glenmark's approved label.","length":173,"tagName":"p","attribs":{}},{"type":"text","content":" 2 All brand names and trademarks are the property of their respective owners.","length":78,"tagName":"p","attribs":{}},{"type":"text","content":" 3 Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenm...